ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025
Enhancing Chemotherapy-Related Immune Responses via Bioorthogonal Metabolic Engineering-Driven Tumor Exosomes Elimination.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Strategies, Challenges and Application Prospects for Exosome Engineering Modifications in Tumor Targeted Therapeutics.International journal of nanomedicine · 2026Review
- Enhancing Chemotherapy-Related Immune Responses via Bioorthogonal Metabolic Engineering-Driven Tumor Exosomes Elimination.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Tumor cell-driven exosomes (TExo) have exhibited several major drawbacks that hinder antitumor therapy. A representative immunosuppressive mechanism is the depletion of CD8+ cytotoxic T cells with the help of exosomal PD-L1. Another common mechanism is to promote tumor metastasis by promoting the seeding and growth of metastatic cancer cells in distant organs. Therefore, the removal of TExo can provide many benefits for the treatment of cancer patients. Here, a bioorthogonal reaction-driven exosome elimination (Biordee) strategy that promoted macrophage-mediated phagocytosis by using IgG Fc to engineer endogenous TExo (TExo-Fc) was developed. The Biordee strategy effectively reduced the levels of TExo in the circulatory system by leveraging the interaction of IgG Fc with FcγRII/III receptors of macrophage, which further broke down the body's immunosuppression and enhanced the immune response after chemotherapy. Moreover, the Biordee strategy inhibited breast cancer liver metastases, which were enhanced by promoting chemotherapy-induced TExo release. This work provided a new attempt to reduce TExo level after chemotherapy to enhance antitumor therapeutic effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.